Rare disorders on a global scale: Understanding the landscape


Soma Das*, Rajdip Goswami
Assistant Professor, Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, Barasat, Kolkata, West Bengal -7000126
Email: somapharma@gmail.com

Abstract
"Rare Disorders on a Global Scale: Understanding the Landscape" explores the complex global fabric of rare diseases, looking at their effect, prevalence, and difficulties. This sheds light on the epidemiology, obstacles to diagnosis, gaps in therapy, and the urgent need for cooperation between researchers, medical practitioners, and politicians to meet the particular requirement of people with uncommon disorders. This study intends to raise awareness, aid in early detection, and improve the standard of treatment for individuals with uncommon diseases worldwide by thoroughly examining this environment.

Keywords: Rare Disorders, Epidemiology, Diagnosis, Collaboration

1. Introduction
Beyond national and cultural borders, rare illnesses pose a complicated range of medical issues. These disorders, which are all characterized by low population prevalence, provide substantial challenges to global healthcare systems (1,2). Rare illnesses, though uncommon in and of itself, have a significant cumulative effect on millions of people worldwide. A comprehensive strategy that incorporates epidemiological surveillance, diagnostic methods, treatment plans, and cooperative efforts across other sectors is necessary to navigate the terrain of rare diseases (3,4). This introduction lays the groundwork for an investigation into the complex global dynamics surrounding rare diseases, including their consequences, prevalence, and the range of difficulties encountered by patients and healthcare professionals Through shedding light on the epidemiology of uncommon illnesses, tackling obstacles to precise diagnosis, and pinpointing deficiencies in current therapies, we emphasize the pressing necessity of cooperation between scholars, medical professionals, and decision-makers (5–7). By working together, we hope to address the special needs of people who have rare diseases, raise awareness, help with early detection, and eventually improve care quality worldwide (8)

2. Background and significance
Rare disorders are a broad category of illnesses that only afflict a small percentage of the population. Although these conditions are uncommon on their own, it is believed that 300 million people worldwide are afflicted by them collectively(9–12). These disorders are uncommon, which makes it difficult to diagnose, manage, and have access to specialized care. Furthermore, patients and their families frequently experience a sense of undervaluation and isolation due to a lack of funding and awareness for research. Comprehending the terrain of uncommon illnesses is essential for enhancing patient results and tackling unfulfilled medical requirements worldwide (11–14).

3. Objectives of the study

The objectives of this study are to give a general overview of the epidemiology of rare conditions, including information on their prevalence and geographic distribution. Examine the difficulties in identifying uncommon diseases, including concerns about awareness, instruction, and availability of genetic testing (15,16). Determine where therapeutic solutions for uncommon conditions are lacking, such as inaccessible orphan medications and restricted therapy options. Emphasize cooperative initiatives and policy ramifications, such as regulatory frameworks and multi-stakeholder engagement, for meeting the needs of people with rare illnesses (17–20). Educate about screening programs, public health initiatives, and provider education that might help raise awareness and improve early detection of rare conditions (21). Suggest recommendations for methods to raise the bar for the treatment of people with uncommon diseases, such as the use of integrated care models, palliative and supportive care, and new developments in research and innovation (22).

4. Epidemiology of rare disorders

Less than 1 in 2,000 people are usually affected with rare ailments, which are characterized by their low prevalence (23). These disorders cover a broad spectrum of illnesses, such as some malignancies and viral, autoimmune, and genetic diseases. Region-specific classification schemes may incorporate factors related to treatment choices' accessibility, severity, and frequency (24,25).

4.1. Global prevalence rates

There are large regional variations in the prevalence of rare disorders, with certain conditions being more common in particular ethnic or geographic groups. Even though they are uncommon on their own, collectively rare disorders impact a sizable percentage of the world's population, underscoring the necessity of raising awareness and stepping up research (26,27).

4.2. Geographic distribution

Rare diseases are present in populations all throughout the world, with differing rate of prevalence noted in various locales. The distribution of rare disorders within populations can be influenced by a number of factors, including genetic predisposition, environmental exposures, and availability to medical care. Comprehending the spatial arrangement of uncommon illnesses is imperative for focused screening, diagnosis, and therapeutic endeavors (27–29).

Table 1. Population data on rare diseases in South Asian countries highlights significant healthcare challenges and resource needs

Countries	Rare Diseases and Disorders Population (2,11)
Afghanistan	1530006
Bangladesh	9151081
Bhutan	44099
India	72611605

Maldives	19037
Nepal	1589670
Pakistan	10999800
Sri Lanka	1216656

Table 2. Rare diseases population data in India's union territories reveals critical healthcare challenges and resource needs

Union Territories (India)	Rare Diseases and Disorders Population
Andaman & Nicobar Islands	22797
Chandigarh	63281
Dadra & Nagar Haveli	20571
Daman & Diu	14575
Lakshadweep	3866
NTC of Delhi	1005194
Pondicherry	74668

Table 3. Rare disease population data in Indian states highlights significant healthcare challenges and resource needs

States (India)	Population (2021)	Rare Diseases and Disorders Population
Andhra Pradesh	54046659	5079932
Arunachal Pradesh	1383727	82957
Assam	35607034	1870156
Bihar	128452895	6228278
Chhattisgarh	31945023	1532412
Goa	1564760	87463
Gujarat	63872399	3623018
Haryana	30991437	1521185
Himachal Pradesh	7602350	411391
Jharkhand	38061013	1977974
Karnataka	68383140	3667842
Kerala	35699443	2003261
Madhya Pradesh	85358849	4355854
Maharashtra	123144223	6742378
Manipur	3048718	163305

Meghalaya	3366923	177840
Mizoram	1247953	65461
Nagaland	2405624	118836
Odisha	45784774	2516841
Punjab	30008595	1662254
Rajasthan	85596450	4117261
Sikkim	688263	36461
Tamil Nadu	82344607	4328337
Tripura	4222899	220262
Uttar Pradesh	240928618	11974891
Uttarakhand	11271780	607005
West Bengal	100736567	5480864

5. Challenges in diagnosis

5.1. Lack of education and awareness

Lack of awareness among patients, healthcare professionals, and the public makes diagnosing rare conditions difficult. Numerous uncommon illnesses have vague symptoms or resemble more prevalent illnesses, which can cause delays in diagnosis and incorrect diagnoses. Enhancing knowledge and instruction regarding uncommon illnesses is crucial for prompt identification and treatment (30).

5.2 Misdiagnosis and diagnostic delays

Because rare ailments are uncommon and healthcare professionals are unfamiliar with them, misdiagnosis and diagnostic delays are frequent. Before acquiring a precise diagnosis, patients may have to go through a number of tests and consultations, which might cause delays in starting the right treatment. Erroneous diagnoses can even transpire when symptoms coincide with more prevalent ailments, underscoring the significance of specialized knowledge in uncommon illnesses (31,32).

5.3 Genetic testing and molecular diagnostics

New developments in these fields have completely changed the way rare ailments are diagnosed by enabling more accurate detection of underlying genetic abnormalities. However, particularly in environments with low resources, access to genetic testing and the interpretation of results may be restricted. Furthermore, geneticists, physicians, and bioinformaticians must work together to evaluate genetic variants, which can be difficult at times (33).

6. Gaps in therapeutic interventions

6.1 Restricted treatment alternatives

Few or no specific treatments are often available for uncommon illnesses. Pharmaceutical corporations find it financially difficult to invest in medication development due to the limited patient populations. Patients with uncommon diseases may therefore have to rely on using experimental medicines or off-label usage of currently available pharmaceuticals, which carries additional dangers and unknowns (34–36).

6.2 Access to orphan drugs

For patients with rare disorders, orphan drug pharmaceuticals created especially for the treatment of uncommon disorders can offer potentially life-saving care. However, because of legal restrictions, exorbitant prices, and restricted availability in some areas, obtaining orphan medications can be difficult. The designation of a medicine as an orphan drug, which offers incentives for drug development and marketing approval, is one way to increase access to orphan drugs (37,38).

6.3 Emerging therapeutic strategies

Developing cutting-edge treatments for uncommon diseases, such as gene therapy, cell-based therapy, and targeted molecular medicines, is gaining attention despite the obstacles. These novel strategies have the potential to improve patient outcomes by targeting the underlying causes of uncommon illnesses. Nevertheless, further investigation is required to confirm their safety and effectiveness in medical environments (39–41).

7. Collaborative efforts and policy implications

7.1. Multi-stakeholder collaboration

Working together, researchers, healthcare professionals, patient advocacy organizations, business partners, and legislators can better address the complex issues of rare illnesses. Working together can make it easier to share knowledge, allocate resources, and create all-encompassing management plans for uncommon diseases (7).

7.2. Patient advocacy and support groups

Patient advocacy and support groups are essential for providing resources, raising awareness, and advocating for rare disorder needs. Along with chances for advocacy and research participation, these organizations provide patients and their families with a sense of community and support (5,11).

.

7.3 Orphan drug designation and regulatory frameworks

Pharmaceutical companies are incentivized to develop therapies for uncommon ailments by regulatory frameworks like orphan drug designation. To incentivize investment in medicinal development, orphan drug classification offers market exclusivity, financial incentives, and remission of regulatory fees. Furthermore, regulatory bodies should speed the licensing procedure for orphan medications in order to provide patients with rare conditions with faster access (2,11).



Figure 1. The scenario of rare diseases in India

7.4 Enhancing awareness and early detection

Public health campaigns have the potential to increase awareness of uncommon ailments, encourage early discovery, and lessen the stigma attached to them. To reach a variety of populations, these initiatives may include instructional materials, media outreach, neighborhood gatherings, and social media efforts (4).

7.5 Healthcare provider education

Educating healthcare professionals about uncommon illnesses improves diagnostic accuracy and the standard of care. Programs for continuing medical education, clinical guidelines, and specialized training can improve the knowledge and assurance of healthcare personnel in the management of uncommon conditions (8).

7.6. Screening and diagnostic programs

Early detection and intervention can be facilitated by putting screening and diagnostic programs for rare conditions into place. Initiatives for genetic testing, newborn screening programs, and specialized clinics can assist in identifying people who may be at risk for uncommon conditions and can give them prompt access to diagnostic services and available treatments (20).

8. Improving the standard of care

8.1. Integrative care models

By emphasizing a comprehensive approach to treatment, integrative care models can raise the bar for patients with uncommon diseases. In order to address the complex requirements of patients with rare disorders, these approaches entail the collaboration of multidisciplinary teams of healthcare providers, including specialists, primary care physicians, nurses, social workers, and allied health professionals (22).

8.2. Palliative and supportive care

These services are essential in enhancing the quality of life for people with uncommon diseases and their families. These offerings

9. Conclusion

In summary, rare disorders present a complex healthcare challenge globally, marked by low prevalence and diverse clinical manifestations. Despite these hurdles, advances in genetic testing and therapy offer hope for improved outcomes. Collaboration among stakeholders, along with increased awareness and research, is key to addressing unmet needs. Moving forward, prioritizing education, diagnosis, and treatment accessibility can enhance the lives of millions affected by rare diseases, fostering a future of innovation and support for all.

References

1. Sciascia S, Roccatello D, Salvatore M, Carta C, Cellai LL, Ferrari G, et al. Unmet needs in countries participating in the undiagnosed diseases network international: an international survey considering national health care and economic indicators. Front Public Heal. 2023;11(September):1–13.
2. Chan AYL, Chan VKY, Olsson S, Fan M, Jit M, Gong M, et al. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis. Value Heal [Internet]. 2020;23(12):1580–91.
3. Thakore NJ, Pioro EP, Udeh BL, Lapin BR, Katzan IL. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole. Value Heal [Internet]. 2020;23(12):1543–51.
4. Carlson JJ, Brouwer ED, Kim E, Wright P, McQueen RB. Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation. Value Heal [Internet]. 2020;23(12):1523–33.
5. Mouslim MC, Trujillo AJ, Alexander GC, Segal JB. Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products. Value Heal [Internet]. 2020;23(12):1599–605.
6. Branković I, Malogajski J, Morré SA. Biobanking and translation of human genetics and genomics for infectious diseases. Appl Transl Genomics. 2014;3(2):30–5.
7. Bureau A, Younkin SG, Parker MM, Bailey-Wilson JE, Marazita ML, Murray JC, et al. Inferring rare disease risk variants based on exact probabilities of sharing by multiple affected relatives. Bioinformatics. 2014;30(15):2189–96.
8. Sidi Y, Harel O. Comprehensive Benefit–Risk Assessment of Noninferior Treatments Using Multicriteria Decision Analysis. Value Heal [Internet]. 2020;23(12):1622–9.
9. Mwambari D, Ali FA, Barak C. The impact of open access on knowledge production, consumption and dissemination in Kenya's higher education system. Third World Quarterly. 2022 Jun 3;43(6):1408-24.
10. Sanghera S, Coast J. Measuring quality-adjusted life-years when health fluctuates. Value in Health. 2020 Mar 1;23(3):343-50.
11. Wu Q, Li J, Parrott S, López-López JA, Davies SR, Caldwell DM, et al. Cost-Effectiveness of Different Formats for Delivery of Cognitive Behavioral Therapy for Depression: A Systematic Review Based Economic Model. Value Heal [Internet]. 2020;23(12):1662–70.
12. Information A. Erratum: Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia. Value Heal. 2020;23(12):1671–2.
13. Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, et al. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income. Value Heal [Internet]. 2020;23(12):1552–60.
14. Senanayake S, Graves N, Healy H, Baboolal K, Barnett A, Sypek MP, et al. Donor Kidney Quality and Transplant Outcome: An Economic Evaluation of Contemporary Practice. Value Heal [Internet]. 2020;23(12):1561–9.
15. Cannizzo S, Lorenzoni V, Palla I, Pirri S, Trieste L, Triulzi I, et al. Rare diseases under different levels of economic analysis: Current activities, challenges and perspectives. RMD Open. 2018;4:1–8.
16. Nghiem VT, Vaidya R, Lyman GH, Hershman DL, Ramsey SD, Unger JM. Economic Evaluations in National Cancer Institute–Sponsored Network Cancer Clinical Trials. Value Heal [Internet]. 2020;23(12):1653–61.
17. Barash CI, Kumar D, Angrist M, Bas AN, Bouësseau M charlotte, Cambon-thomsen A, et al. Editorial Board. Appl Transl Genomics. 2014;3(2):i.
18. Drummond MF, Mullins CD. Editorial Board. Value Heal. 2020;23(12):vi.
19. Gomez GB, Mudzengi DL, Bozzani F, Menzies NA, Vassall A. Estimating Cost Functions for Resource Allocation Using Transmission Models: A Case Study of Tuberculosis Case Finding in South Africa. Value Heal [Internet]. 2020;23(12):1606–12.
20. Yan X, He S, Dong D. Determining how far an adult rare disease patient needs to travel for a definitive diagnosis: A cross-sectional examination of the 2018 national rare disease survey in China. Int J Environ Res Public Health. 2020;17(5).
21. Adachi T, El-Hattab AW, Jain R, Nogales Crespo KA, Quirland Lazo CI, Scarpa M, et al. Enhancing Equitable Access to Rare Disease Diagnosis and Treatment around the World: A Review of Evidence, Policies, and Challenges. Int J Environ Res Public Health. 2023;20(6).
22. de Carvalho LSF, Gioppato S, Fernandez MD, Trindade BC, Silva JCQ e., Miranda RGS, et al. Machine Learning Improves the Identification of Individuals With Higher Morbidity and Avoidable Health Costs After Acute Coronary Syndromes. Value Heal [Internet]. 2020;23(12):1570–9.
23. Khodyakov D, Chen C. Nature and Predictors of Response Changes in Modified-Delphi Panels. Value Heal [Internet]. 2020;23(12):1630–8.
24. Rajasimha HK, Shirol PB, Ramamoorthy P, Hegde M, Barde S, Chandru V, et al. Organization for rare diseases India (ORDI)-addressing the challenges and opportunities for the Indian rare diseases' community. Genet Res (Camb). 2014;96.
25. Sharma A, Jacob A, Tandon M, Kumar D. Orphan drug: Development trends and strategies. J Pharm Bioallied Sci. 2010;2(4):290.
26. Agarwal S, Bhattacharjee D, Patil N, Bairy KL. Orphan drugs: The current global and Indian scenario. Asian J Pharm Clin Res. 2016;9(4):46–50.
27. Ouellette S, Tassé AM. P3G - 10years of toolbuilding: From the population biobank to the clinic. Appl Transl Genomics [Internet]. 2014;3(2):36–40.
28. Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? Value Heal [Internet]. 2020;23(12):1613–21.
29. Hong YR, Salloum RG, Yadav S, Smith G, Mainous AG. Patient–Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care. Value Heal [Internet]. 2020;23(12):1592–8.
30. Zang X, Jalal H, Krebs E, Pandya A, Zhou H, Enns B, et al. Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis. Value Heal [Internet]. 2020;23(12):1534–42.
31. Mascalzoni D, Paradiso A, Hansson M. Rare disease research: Breaking the privacy barrier. Appl Transl Genomics [Internet]. 2014;3(2):23–9.
32. Weiss G, Copelton D. The sociology of health, healing, and illness. Routledge; 2020 Aug 11.
33. Choudhury MC, Saberwal G. The role of patient organizations in the rare disease ecosystem in India: an interview based study. Orphanet journal of rare diseases. 2019 Dec;14:1-4.
34. Hossain MS, Raheem E, Sultana TA, Ferdous S, Nahar N, Islam S, et al. Thalassemias in South Asia: clinical lessons learnt from Bangladesh. Orphanet J Rare Dis. 2017;12(1):1–9.
35. Choudhury MC, Saberwal G. The role of patient organizations in the rare disease ecosystem in India: An interview based study. Orphanet J Rare Dis. 2019;14(1):1–14.
36. Hosen MJ, Anwar S, Taslem Mourosi J, Chakraborty S, Miah MF, Vanakker OM. Genetic counseling in the context of Bangladesh: current scenario, challenges, and a framework for genetic service implementation. Orphanet Journal of Rare Diseases. 2021 Apr 9;16(1):168.
37. Salvatore M, Polizzi A, De Stefano MC, Floridia G, Baldovino S, Roccatello D, et al. Improving diagnosis for rare diseases: The experience of the Italian undiagnosed Rare diseases network. Ital J Pediatr. 2020;46(1):1–15.
38. Sivasubbu S, Scaria V. Genomics of rare genetic diseases-experiences from India. Hum Genomics. 2019;14(1):52.
39. Douglas CM, Panagiotoglou D, Dragojlovic N, Lynd L. Methodology for constructing scenarios for health policy research: the case of coverage decision-making for drugs for rare diseases in Canada. Technological Forecasting and Social Change. 2021 Oct 1;171:120960.
40. Knoppers BM, Zawati MH, Cohen E. Special Issue - From Biobanks to the Clinic. Appl Transl Genomics [Internet]. 2014;3(2):21–2.
41. Liu Q, Peng W, Zhang F, Hu R, Li Y, Yan W. The effectiveness of blended learning in health professions: systematic review and meta-analysis. Journal of medical Internet research. 2016 Jan 4;18(1):e2.

Name: _____

Rare Diseases in India

Please unscramble the words below

1. yaoamFrgibli	a disorder characterized by widespread musculoskeletal pain
2. iaxatA	disease without coordination
3. oryucehHdlaps	an abnormal buildup of cerebrospinal fluid in the ventricles
4. osoiilAsdmy	rare disease associated with amyloid buildup
5. narlrmeBlSGradoiyunei	rare autoimmune disorder affects the nerves

Answers are on page 186